Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood

Study Overview
=================
Brief Summary
-----------------
Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is linked to a better prognosis. Further, surgical resection at the early stages of non-small cell lung cancer (NSCLC) results in markedly improved survival rates. Computed tomography (CT)- or bronchoscopy-guided needle biopsies are standard definitive diagnostic procedures for lung cancer and are used to obtain tissue for pathological examination. However, these procedures are invasive, difficult to repeat, expensive, and risk exposure to radiation. Conversely, liquid biopsies, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), are simple and less invasive procedures that can be repeated more frequently than tissue biopsies. This study is a retrospective blood sample obtained and prospectively comparative analysis of various biomarkers (cancer markers, and exosome markers) derived from peripheral blood and pulmonary venous blood from patients who underwent lung cancer surgery. And treatment monitoring using biomarkers compare with peripheral and pulmonary blood.

Official Title
-----------------
A Retrospective Study to Compare Biomarker Expression of Exosomes Derived From Peripheral Blood and Primary Lung Cancer Drainage Pulmonary Blood in Lung Cancer Patients

Conditions
-----------------
Lung Cancer, Diagnosis

Intervention / Treatment
-----------------
* Diagnostic Test: frozen blood plasma samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults with Korean nationality Patients who did not receive neoadjuvant therapy before surgery Patients not diagnosed with any other cancer before surgery Patients who agreed to the consent form for a donation of human materials during surgery Exclusion Criteria: Patients who do not meet the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: frozen blood plasma samples|Analysis of various biomarkers using frozen blood samples|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparative analysis of cancer marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein | Comparative analysis of CEA and lung cancer-specific exosome marker concentrations in peripheral blood and pulmonary blood using ELISA assay Characterization of exosomes using western blot, NTA, and TEM analysis | 2020   2025 | 
| Diagnostic analysis of lung cancer-specific exosome marker concentrations in a peripheral vein and primary lung cancer outflow pulmonary vein | 1) Evaluation of the clinical usefulness of lung cancer diagnosis using lung cancer-specific exosome markers in peripheral vein blood and primary lung cancer outflow pulmonary vein-derived blood. | 2020   2025 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of lung cancer treatment monitoring using lung cancer-specific exosome biomarkers | Clinical evaluation of recurrence or cancer metastasis after treatment in patients who underwent lung cancer surgery using lung cancer-specific exosome biomarkers according to blood sample location (peripheral vein blood and primary lung cancer outflow pulmonary vein derived blood) | 2020   2025 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exosome, biomarker, lung cancer, diagnosis, prognosis, liquid biopsy